Keynote Session: CAR T-cell Therapy - Focus on Leukemia
Chimeric antigen receptor (CAR) T-cell therapy is an emerging immune-based therapy used in cancer treatment. It has demonstrated significant impact in the management of hematologic malignancies, including B-cell acute lymphoblastic leukemia (B-ALL).
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Keynote Session: CAR T-cell Therapy - Historical Perspectives and Major Milestones
Chimeric antigen receptor (CAR) T-cell therapy is an immune-based therapy used in cancer treatment that has demonstrated efficacy in the management of many hematologic malignancies, suggesting significant impact on oncology practice.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing the Care of Patients Receiving CAR T-Cell Therapy
Patients with relapsed or refractory hematologic disorders like acute lymphoblastic leukemia and diffuse large B-cell lymphoma have poor outcomes and require novel effective therapies.
Category
  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Acute Lymphoblastic Leukemia, Version 1.2019
Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation